A new blood test could help predict whether women with breast cancer will respond to treatment before it begins.
Scientists at the Institute of Cancer Research in London said the “liquid biopsy” can detect genetic changes in the tumours of patients and indicate if they are less likely to respond to a new targeted drug.
These genetic changes can also predict whether a patient’s disease is likely to return.
The research was presented at the annual meeting of the American Society of Clinical Oncology in Chicago.
Professor Paul Workman, chief executive of the Institute of Cancer Research, said: “Cancer’s ability to evolve to become resistant to treatment is the greatest challenge we face in improving patients’ survival and quality of life.
“So-called liquid biopsy tests like this one are a key part of our toolkit in staying on top of cancers’ adaptability and evolution, and picking up the earliest signs of drug resistance.
“Detecting the potential of cancers to evolve resistance could allow us to predict cancer’s next move and to respond with adaptable new treatment plans.”
Unfortunately many tumours which initially respond will later develop resistance and come backProfessor Nicholas Turner
Fragments of cancer DNA in the blood samples of 310 women with oestrogen receptor positive breast cancer – the most common form of the disease – were analysed during the study.
The patients had advanced breast cancer and were taking part in a trial of targeted drug palbociclib and hormone therapy fulvestrant.
The research team found 42% of the women had one or more of three changes in the tumour DNA in their bloodstream that put them at risk of early relapse.
Women whose circulating tumour DNA contained changes in the cancer gene p53 saw their cancer return after an average of 3.7 months.
This compared to 12.7 months among women without the gene changes.
An increase in other genes was also found to predict when the cancer might return.
Professor Nicholas Turner, from the Institute of Cancer Research and Royal Marsden, said: “Exciting new targeted treatments like palbociclib are beginning to have a real impact on survival for women with breast cancer, but unfortunately many tumours which initially respond will later develop resistance and come back.
“Our study found that a new genetic test could detect right at the start of treatment those women whose cancers were most likely to develop resistance quickly to palbociclib.
“We could then adjust their treatment plan accordingly – trialling additional treatments from the outset to try and prevent resistance, or planning for a switch to another treatment as soon as resistance develops.
“We now need to assess in a clinical trial whether helping direct women’s care with this new test can offer improved survival and quality of life.”
Dr Kotryna Temcinaite, research communications manager at Breast Cancer Care and Breast Cancer Now, which helped fund the study, said: “It’s really encouraging that using a blood test to understand genetic changes in tumours could help us identify which cancers are likely to develop resistance to vital new therapies like palbociclib at the earliest possible stage.
“While very effective treatments for many, some people can experience side-effects that are really difficult to cope with and have a major impact on their daily lives – so we urgently need to find ways to identify whether these drugs are likely to work.”